Search

Displaying results 7261 - 7270 of 10000 in total
  1. Drug

    ABX-PTH

    go.drugbank.com/drugs/DB05883
    Experimental

    ABX-PTH is a fully human monoclonal antibody generated by Abgenix's technology platform. … This drug targets and neutralizes the action of parathyroid hormone (PTH) for the treatment of a secondary hyperparathyroidism.

  2. Drug

    GT 389-255

    go.drugbank.com/drugs/DB05894
    Experimental

    Peptimmune’s lead product GT 389-255, is a novel lipase inhibitor and fat binding hydrogel polymer conjugate for the treatment of obesity which has completed single and multiple ascending dose (SAD and

  3. Drug

    rhIGFBP-3

    go.drugbank.com/drugs/DB05897
    Investigational

    rhIGFBP-3 (recombinant human insulin-like growth factor binding protein-3) is Insmed’s proprietary anti-cancer compound that has demonstrated significant decreases in cancerous growth in several models of human. It is developed by Insmed...

  4. Drug

    PRTX-100

    go.drugbank.com/drugs/DB05947
    Investigational

    PRTX-100 is a highly-purified form of Staphylococcal Protein A that binds directly to monocytes and a subset of B-cells that are involved in the development and progression of various autoimmune diseases

    Synonyms: Staphylococcus aureus protein A
  5. Drug

    PPL-100

    go.drugbank.com/drugs/DB05961
    Investigational

  6. Drug

    ANZ-100

    go.drugbank.com/drugs/DB05967
    Investigational

  7. Drug

    Archexin

    go.drugbank.com/drugs/DB05971
    Investigational

    Synonyms: 5'-DG-DC-T-DG-DC-DA-T-DG-DA-T-DC-T-DC-DC-T-T-DG-DG-DC-DG-3', 5'-DG-DC-T-DG-DC-DA-T-DG-DA-T-DC-T-DC-DC-T-T-DG-DG-DC-DG-3', SODIUM PHOSPHOTHIOATE
  8. Drug

    PR-15

    go.drugbank.com/drugs/DB06037
    Investigational

    PR-15 is a novel anti-platelet protein with the potential to treat arterial thrombosis occurring during acute coronary syndromes without the bleeding risk associated with existing agents.

  9. Drug

    POT-4

    go.drugbank.com/drugs/DB06056
    Investigational

    POT-4 is a peptide that specifically inhibits complement activation and is initially being developed for the treatment of age-related macular degeneration (AMD).

  10. Drug

    XTL-6865

    go.drugbank.com/drugs/DB06058
    Investigational

    It is being developed to prevent HCV re-infection following a liver transplant and for the treatment of chronic HCV disease. … XTL-6865 is a combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis C virus E2 envelope protein.